JP2023525778A5 - - Google Patents

Info

Publication number
JP2023525778A5
JP2023525778A5 JP2022568460A JP2022568460A JP2023525778A5 JP 2023525778 A5 JP2023525778 A5 JP 2023525778A5 JP 2022568460 A JP2022568460 A JP 2022568460A JP 2022568460 A JP2022568460 A JP 2022568460A JP 2023525778 A5 JP2023525778 A5 JP 2023525778A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequences
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525778A (ja
Filing date
Publication date
Priority claimed from CN202010394296.5A external-priority patent/CN113637073B/zh
Application filed filed Critical
Publication of JP2023525778A publication Critical patent/JP2023525778A/ja
Publication of JP2023525778A5 publication Critical patent/JP2023525778A5/ja
Pending legal-status Critical Current

Links

JP2022568460A 2020-05-11 2021-05-07 抗ｂｃｍａ抗体およびキメラ抗原受容体 Pending JP2023525778A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010394296.5A CN113637073B (zh) 2020-05-11 2020-05-11 Bcma抗体及其制备和应用
CN2020103942965 2020-05-11
PCT/US2021/031299 WO2021231213A1 (en) 2020-05-11 2021-05-07 Anti-bcma antibodies and chimeric antigen receptors

Publications (2)

Publication Number Publication Date
JP2023525778A JP2023525778A (ja) 2023-06-19
JP2023525778A5 true JP2023525778A5 (https=) 2024-02-21

Family

ID=78415523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568460A Pending JP2023525778A (ja) 2020-05-11 2021-05-07 抗ｂｃｍａ抗体およびキメラ抗原受容体

Country Status (4)

Country Link
EP (1) EP4149967A4 (https=)
JP (1) JP2023525778A (https=)
CN (1) CN113637073B (https=)
WO (1) WO2021231213A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023116759A1 (zh) * 2021-12-22 2023-06-29 上海君实生物医药科技股份有限公司 抗bcma抗体及其用途
CN116063521B (zh) * 2022-10-31 2024-05-14 北京奇迈永华生物科技有限公司 靶向bcma的抗体及其所构成的嵌合抗原受体
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2026006767A1 (en) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Tethered il-9/il-9r and related engineered cells and methods
CN119119274A (zh) * 2024-09-26 2024-12-13 北京昌盛鸿途生物科技有限公司 一种靶向bcma的cart细胞及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201634479A (zh) * 2007-12-05 2016-10-01 中外製藥股份有限公司 抗ｎｒ１０抗體及其應用
CN102272158B (zh) * 2008-11-12 2014-05-07 乔治·K·刘易斯 源自记忆b细胞的人单克隆抗体的快速表达克隆
EA033604B1 (ru) * 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
EP3131927B8 (en) * 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
KR102526945B1 (ko) * 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
PE20171790A1 (es) * 2015-03-23 2017-12-28 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos
JP7114460B2 (ja) * 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
MX2018002043A (es) * 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
CN105777911B (zh) * 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
US20170298119A1 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
MA51447A (fr) * 2017-08-01 2020-06-10 Medimmune Llc Conjugué anticorps monoclonal-médicament dirigé contre bcma
CN116836297A (zh) * 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用

Similar Documents

Publication Publication Date Title
JP2023525778A5 (https=)
IL317912A (en) A combined chimeric antigen receptor targeting CD19 and CD20 and its applications
US20230322920A1 (en) Multi-specific antibodies and methods of making and using thereof
Labrijn et al. Bispecific antibodies: a mechanistic review of the pipeline
JP2025028239A5 (https=)
JP5851419B2 (ja) ヘテロダイマー結合タンパク質およびその使用
JP2023553390A5 (https=)
JP2021087455A5 (https=)
JP7854121B2 (ja) 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法
JP2021526844A5 (https=)
JP2020010699A5 (https=)
US11787863B2 (en) Multi-specific antibodies and methods of making and using thereof
JP2018525382A5 (https=)
JP2022551757A5 (https=)
JP2017524367A5 (https=)
JP2017522879A5 (https=)
AU2022380722A1 (en) Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
JP2024537772A5 (https=)
IL311600A (en) Antibodies targeting BAFF-R and their use
JP2024539506A5 (https=)
JP2022508529A (ja) 二重標的抗原結合分子
US20250043001A1 (en) Anti-cd28 compositions
JP2021524451A (ja) 最適化済みｇｐ４１結合分子及びその使用
JP7503215B2 (ja) Ｃｄ３０及びｃｄ３に結合する抗体
Fine et al. Mechanism-driven design of multispecific antibodies for targeted disease treatment